荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02509 荃信生物-B

休市中 11-22 16:08:13

9.080

+0.150

+1.68%

最高9.310	最低9.080	成交量1.02万
今开9.130	昨收8.930	日振幅2.58%
总市值20.16亿	流通市值18.61亿	总股本2.22亿
成交额9.40万	换手率0.00%	流通股本2.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":9.08,"timestamp":1732262893017,"preClose":8.93,"halted":0,"volume":10200,"delay":0,"floatShares":204999999,"shares":222071600,"eps":-2.6476834,"marketStatus":"休市中","marketStatusCode":7,"change":0.15,"latestTime":"11-22 16:08:13","open":9.13,"high":9.31,"low":9.08,"amount":94030,"amplitude":0.025756,"askPrice":0,"askSize":0,"bidPrice":9.08,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-2.11945712602857,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":1710864000000,"adjPreClose":8.93,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":0.095291,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509","defaultTab":"news","newsList":[{"id":"2485368662","title":"荃信生物-B(02509)认购浦发银行提供的两项理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2485368662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485368662?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:51","pubTimestamp":1732265469,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2024年11月22日，为有效利用闲置资金，公司与浦发银行签订了两份认购协议，以认购由浦发银行提供的两项理财产品，其主要条款载列如下。公司同意认购由浦发银行发售的理财产品，本金金额为人民币6000万元，到期日为2025年2月25日。公司同意认购由浦发银行发售的理财产品，本金金额为人民币1亿元，到期日为2025年2月25日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SGXZ49509284.SGD","BK1161","BK0187","LU0469268626.HKD","LU1808992512.USD","BK0015","BK0201","BK0183","LU1979443071.USD","SGXZ81163826.USD","02509","600000","BK0188","BK0086","LU1934453819.USD","BK0012","BK0028","BK0278"],"gpt_icon":0},{"id":"2485236219","title":"荃信生物(02509.HK)以1.6亿元人币认购两项理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2485236219","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485236219?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:47","pubTimestamp":1732265220,"startTime":"0","endTime":"0","summary":"荃信生物-B(02509.HK) 公布，以1.6亿元人民币认购由浦发银行(600000.SH) 提供的两项理财产品，到期日同为明年2月25日。(vc/da)(港股报价延迟最少十五分钟。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240312084301695_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240312084301695_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398903/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2484815611","title":"港股异动 | 荃信生物-B(02509)现涨超6% QX001S获国家药品监督管理局核准签发的药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2484815611","media":"智通财经","labels":["Product Release","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484815611?lang=zh_cn&edition=full","pubTime":"2024-11-20 14:07","pubTimestamp":1732082868,"startTime":"0","endTime":"0","summary":"消息面上，荃信生物公布，11月5日，中美华东收到国家药品监督管理局核准签发的《药品注册证书》，由中美华东申报的乌司奴单抗注射液的上市许可申请获得批准，用于治疗成年中重度斑块状银屑病。QX001S是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2484158287","title":"荃信生物-B盘中异动 大幅上涨6.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484158287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484158287?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:09","pubTimestamp":1732079354,"startTime":"0","endTime":"0","summary":"2024年11月20日下午盘13时09分，荃信生物-B股票出现波动，股价快速上涨6.59%。截至发稿，该股报8.900港元/股，成交量3600股，换手率0.00%，振幅19.16%。荃信生物-B股票所在的生物技术行业中，整体涨幅为2.33%。其相关个股中，来凯医药-B、科伦博泰生物-B、晶泰科技涨幅较大，振幅较大的相关个股有来凯医药-B、荃信生物-B、晶泰科技，振幅分别为38.11%、19.16%、19.00%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120130914a24790cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120130914a24790cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2484395259","title":"荃信生物-B盘中异动 早盘股价大涨5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484395259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484395259?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:27","pubTimestamp":1731986831,"startTime":"0","endTime":"0","summary":"2024年11月19日早盘11时27分，荃信生物-B股票出现异动，股价急速拉升5.51%。截至发稿，该股报9.000港元/股，成交量1.02万股，换手率0.00%，振幅7.74%。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，云顶新耀-B、正大企业国际、康希诺生物涨幅较大，振幅较大的相关个股有晶泰科技、百奥赛图-B、腾盛博药-B，振幅分别为15.28%、9.67%、8.33%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111911271298e4368a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111911271298e4368a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2484595214","title":"荃信生物－Ｂ(02509)股价上升5.51%，现价港币$9.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2484595214","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484595214?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:27","pubTimestamp":1731986820,"startTime":"0","endTime":"0","summary":"[上升股]荃信生物－Ｂ(02509) 股价在上午11:27比前收市价上升5.51%，现股价为港币$9.0。至目前为止，今日最高价为$9.0，而最低价为$8.34。总成交量为1.02万股，总成交金额为港币$8.861万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241119856/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2484698315","title":"荃信生物-B(02509)下跌14.17%，报8.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484698315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484698315?lang=zh_cn&edition=full","pubTime":"2024-11-18 10:47","pubTimestamp":1731898052,"startTime":"0","endTime":"0","summary":"11月18日，荃信生物-B(02509)盘中下跌14.17%，截至10:47，报8.6元/股，成交101.1万元。江苏荃信生物医药股份有限公司的主营业务是研发自身免疫及过敏性疾病的生物疗法。公司现有1个品种BLA已受理，1个品种处于临床3期，4个品种分别处于临床2期及1期，产品覆盖皮肤、风湿、呼吸、消化等领域，拥有及申报的国内外专利达90余项。截至2024年中报，荃信生物-B营业总收入4491.9万元、净利润-1.72亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18104745388097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2484667900","title":"荃信生物-B盘中异动 大幅下挫5.19%报9.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484667900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484667900?lang=zh_cn&edition=full","pubTime":"2024-11-18 10:27","pubTimestamp":1731896857,"startTime":"0","endTime":"0","summary":"2024年11月18日早盘10时27分，荃信生物-B股票出现波动，股价急速跳水5.19%。截至发稿，该股报9.500港元/股，成交量4400股，换手率0.00%，振幅5.19%。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.74%。其相关个股中，科济药业-B、君实生物、贝康医疗-B涨幅较大，振幅较大的相关个股有正大企业国际、晶泰科技、百奥赛图-B，振幅分别为15.43%、11.96%、11.15%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111810273798e431d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111810273798e431d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2483318640","title":"荃信生物-B(02509)下跌21.08%，报10.26元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483318640","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483318640?lang=zh_cn&edition=full","pubTime":"2024-11-15 13:27","pubTimestamp":1731648441,"startTime":"0","endTime":"0","summary":"11月15日，荃信生物-B(02509)盘中下跌21.08%，截至13:27，报10.26元/股，成交107.14万元。江苏荃信生物医药股份有限公司的主营业务是研发自身免疫及过敏性疾病的生物疗法。公司现有1个品种BLA已受理，1个品种处于临床3期，4个品种分别处于临床2期及1期，产品覆盖皮肤、风湿、呼吸、消化等领域，拥有及申报的国内外专利达90余项。截至2024年中报，荃信生物-B营业总收入4491.9万元、净利润-1.72亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/15132745329326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2483367575","title":"荃信生物-B盘中异动 急速下挫6.15%报12.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483367575","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483367575?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:35","pubTimestamp":1731634552,"startTime":"0","endTime":"0","summary":"2024年11月15日早盘09时35分，荃信生物-B股票出现波动，股价急速下挫6.15%。截至发稿，该股报12.200港元/股，成交量1.02万股，换手率0.00%，振幅6.15%。资金方面，该股资金流入0港元，流出12.46万港元。荃信生物-B股票所在的生物技术行业中，整体涨幅为0.09%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事自体免疫及过敏性疾病生物疗法的生物科技研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115093552abc2ab1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115093552abc2ab1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2481141161","title":"荃信生物-B盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481141161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481141161?lang=zh_cn&edition=full","pubTime":"2024-11-08 14:18","pubTimestamp":1731046739,"startTime":"0","endTime":"0","summary":"2024年11月08日下午盘14时18分，荃信生物-B股票出现异动，股价急速下跌5.04%。荃信生物-B股票所在的生物技术行业中，整体涨幅为0.29%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。该信息摘要如下：荃信生物称，赛乐信是中国首个获批的乌司奴单抗注射液生物类似药，同时也是荃信生物首个商业化的产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110814190198e41674&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110814190198e41674&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2481313646","title":"国内首个！荃信生物与华东医药联合开发的乌司奴单抗注射液赛乐信 上市许可申请获批 |【经纬低调新闻】","url":"https://stock-news.laohu8.com/highlight/detail?id=2481313646","media":"经纬创投","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481313646?lang=zh_cn&edition=full","pubTime":"2024-11-06 12:08","pubTimestamp":1730866080,"startTime":"0","endTime":"0","summary":"综述2024年11月5日，华东医药股份有限公司下属杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》，由中美华东与江苏荃信生物医药股份有限公司联合开发的乌司奴单抗注射液赛乐信的上市许可申请获得批准，用于治疗成年中重度斑块状银屑病。QX001S是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3ODk5OTEzOA==&mid=2962179981&idx=2&sn=18100ea85e714fe2425a6769887f7296&chksm=ab0b93380a120cac3d27f7c9fb12958e1f95416734fc791f56dd907396c4f8dc354765035c38&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0175","000963","BK0183","BK0196","02509","BK0187","BK1161","LU2328871848.SGD","BK0132","LU1969619763.USD","BK0188","BK0209"],"gpt_icon":0},{"id":"2481198690","title":"荃信生物-B早盘涨超7% 乌司奴单抗注射液上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2481198690","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481198690?lang=zh_cn&edition=full","pubTime":"2024-11-06 11:08","pubTimestamp":1730862480,"startTime":"0","endTime":"0","summary":"　　荃信生物-B早盘上涨7.69%，现报14港元，成交额45.10万港元。　　荃信生物公布，11月5日，中美华东收到国家药品监督管理局核准签发的《药品注册证书》，由中美华东申报的乌司奴单抗注射液的上市许可申请获得批准，用于治疗成年中重度斑块状银屑病。QX001S是公司研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-06/doc-incvauei0388117.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-06/doc-incvauei0388117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2481692416","title":"港股异动 | 荃信生物-B(02509)涨超7% 乌司奴单抗注射液上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2481692416","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481692416?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:40","pubTimestamp":1730860823,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超7%，截至发稿，涨7.69%，报14港元，成交额45.1万港元。消息面上，荃信生物公布，11月5日，中美华东收到国家药品监督管理局核准签发的《药品注册证书》，由中美华东申报的乌司奴单抗注射液的上市许可申请获得批准，用于治疗成年中重度斑块状银屑病。QX001S是公司研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2481905696","title":"荃信生物－Ｂ(02509)股价上升9.077%，现价港币$14.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2481905696","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481905696?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:35","pubTimestamp":1730856900,"startTime":"0","endTime":"0","summary":"[上升股]荃信生物－Ｂ(02509) 股价在上午09:35比前收市价上升9.077%，现股价为港币$14.18。至目前为止，今日最高价为$14.18，而最低价为$14.18。总成交量为200股，总成交金额为港币$2836。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241106217/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2481952176","title":"荃信生物-B盘中异动 股价大涨6.15%报13.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481952176","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481952176?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:34","pubTimestamp":1730856877,"startTime":"0","endTime":"0","summary":"2024年11月06日早盘09时34分，荃信生物-B股票出现波动，股价急速拉升6.15%。截至发稿，该股报13.800港元/股，成交量0股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出0港元。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，荃信生物-B、亚盛医药-B、金斯瑞生物科技涨幅较大，振幅较大的相关个股有科济药业-B、歌礼制药-B、巨子生物，振幅分别为6.68%、5.56%、4.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110609343998e40add&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110609343998e40add&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2481660396","title":"智通港股早知道 | 工信部将培育更多低空产业头部企业和专精特新“小巨人”企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2481660396","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481660396?lang=zh_cn&edition=full","pubTime":"2024-11-06 07:29","pubTimestamp":1730849347,"startTime":"0","endTime":"0","summary":"要抓好重点企业，加强企业梯度培育，推动产业链上下游企业协同创新发展，培育更多低空产业头部企业和专精特新“小巨人”企业。此举旨在推动国内各产业下游发展，预计将吸引高达6180亿美元的投资。这一政策或将对全球相关市场产生深远影响。国泰君安换股合并海通证券获上海市政府批复同意证券行业的超级航母落地迎来新进展。投产后，小米两座工厂将提供总计30万辆的额定年产能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03996","YANG","00064","BK1123","BK1147","HSCEI","00753","02509","BK1561","BK1161","DJT","BK1505","BK1148","HSTECH","BK1514"],"gpt_icon":1},{"id":"2481669519","title":"荃信生物首款商业化产品获批 合作方华东医药：对业绩有一定作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2481669519","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481669519?lang=zh_cn&edition=full","pubTime":"2024-11-05 20:49","pubTimestamp":1730810952,"startTime":"0","endTime":"0","summary":"荃信生物称，赛乐信是中国首个获批的乌司奴单抗注射液生物类似药，同时也是荃信生物首个商业化的产品。华东医药5日晚间发布公告称，在赛乐信项目研发直接投入总金额约1.59亿元，赛乐信获批上市，有望为中国银屑病患者带来更多用药选择。华东医药表示，赛乐信的上市不会对当前财务状况和经营成果产生重大影响，对未来业绩提升有一定积极作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106073037a219a71d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106073037a219a71d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2481762045","title":"荃信生物-B：QX001S(赛乐信，乌司奴单抗注射液)获国家药品监督管理局核准签","url":"https://stock-news.laohu8.com/highlight/detail?id=2481762045","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481762045?lang=zh_cn&edition=full","pubTime":"2024-11-05 18:44","pubTimestamp":1730803466,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 荃信生物-B (02509.HK)发布公告，2024年11月5日，中美华东收到国家药品监督管理局(NMPA)核准签发的《药品注册证书》，由中美华东申报的乌司奴单抗注射液(商品名：赛乐信，研发代号：QX001S/HDM3001)的上市许可申请获得批准，用于治疗成年中重度斑块状银屑病。QX001S最初由公司自主研发，2020年8月，公司与中美华东达成合作，由双方共同推进QX001S的III期临床试验，中美华东作为上市许可持有人负责中国大陆区域商业化，赛孚士负责产品生产及供应。QX001S是公司研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105185031a21840d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105185031a21840d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2481435522","title":"荃信生物(02509.HK)QX001S获国家药监局核准签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481435522","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481435522?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:34","pubTimestamp":1730799240,"startTime":"0","endTime":"0","summary":"荃信生物-B公布，中美华东收到国家药品监督管理局核准签发的《药品注册证书》，由中美华东申报的乌司奴单抗注射液的上市许可申请获得批准，用于治疗成年中重度斑块状银屑病。QX001S是集团研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240325152227966_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240325152227966_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1394288/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02509"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":-0.0938},{"period":"1month","weight":-0.3314},{"period":"3month","weight":-0.6177},{"period":"6month","weight":-0.6769},{"period":"1year","weight":-0.5414},{"period":"ytd","weight":-0.5414}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0737},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0334},{"period":"1year","weight":0.0736},{"period":"ytd","weight":0.128}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事自身免疫及过敏性疾病生物疗法的生物科技研发。该公司业务主要涵盖四大疾病领域，包括皮肤、风湿、呼吸道及消化道疾病。该公司正在研发的项目有8个，目标适应症包括银屑病、特应性皮炎、类风湿性关节炎、炎症性肠病、哮喘等。该公司核心产品有QX002N和QX005N。","exchange":"SEHK","name":"荃信生物-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荃信生物-B,02509,荃信生物-B股票,荃信生物-B股票老虎,荃信生物-B股票老虎国际,荃信生物-B行情,荃信生物-B股票行情,荃信生物-B股价,荃信生物-B股市,荃信生物-B股票价格,荃信生物-B股票交易,荃信生物-B股票购买,荃信生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}